Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InBody CoXKRX:041830 +1.19%88 OCF Yield % is 4.99 as of Sep. 03, 2026, which is 43% below its 10-year median of 8.77. GuruFocus rates XKRX:041830 with a GF Score™ of 88/100 and a GF Value™ of ₩35,473.99 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 850 Medical Devices & Instruments companies, InBody Co ranks better than 66.71% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for InBody Co's OCF Yield % or its related term are showing as below:
XKRX:041830'
s OCF Yield % Range Over the Past 10 Years
Min: 2.02 Med: 8.77 Max: 13.45
Current: 4.99
During the past 13 years, the highest OCF Yield % of InBody Co was 13.45%. The lowest was 2.02%. And the median was 8.77%.
XKRX:041830's OCF Yield % is ranked better than 66.71% of 850
companies
in the Medical Devices & Instruments industry
Industry Median: 1.785
vs XKRX:041830: 4.99
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
InBody Co OCF Yield % Related Terms
InBody Co OCF Yield % Historical Data
* Premium members only.
The historical data trend for InBody Co's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKRX:041830 vs ABT, SYK, MDT: OCF Yield % Comparison
For the Medical Devices subindustry, InBody Co's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InBody Co OCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InBody Co's OCF Yield % distribution charts can be found below:
* The bar in red indicates where InBody Co's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InBody Co (XKRX:041830) has a OCF Yield % of 4.99 as of Sep. 03, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on InBody Co and its competitors. This is 43% below median its historical median of 8.77. Over the past decade, InBody Co's OCF Yield % has ranged from 2.02 to 13.45. According to the industry distribution chart, InBody Co ranks #283 out of 850 companies in the Medical Devices & Instruments industry, placing it in the top 33.3%.
Is InBody Co's OCF Yield % too high?
InBody Co's current OCF Yield % of 4.99 is 43% below median its 10-year median of 8.77. Over the past 10 years, this metric has ranged from a low of 2.02 to a high of 13.45. The Medical Devices & Instruments industry median OCF Yield % is 1.79. InBody Co's value of 4.99 is 179.6% above this industry median. Based on the distribution chart, InBody Co ranks #283 out of 850 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, InBody Co has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InBody Co's OCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, InBody Co ranks #283 out of 850 companies for OCF Yield %. This puts InBody Co in the upper half of its industry. The industry median OCF Yield % is 1.79. InBody Co's value of 4.99 is 179.6% above this benchmark. Historically, InBody Co's own OCF Yield % has ranged from 2.02 to 13.45 over the past decade. While the company's 10-year median is 8.77 vs. the industry median of 1.79, InBody Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Devices & Instruments company?
The median OCF Yield % among Medical Devices & Instruments companies is 1.79, based on 850 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InBody Co's current OCF Yield % of 4.99 is 179.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on InBody Co and its competitors. For the Medical Devices & Instruments industry, the median OCF Yield % is 1.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InBody Co's current OCF Yield % is 4.99, which is 43% below median its own 10-year median of 8.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InBody Co stock overvalued right now?
Based on GuruFocus' analysis, InBody Co (XKRX:041830) is currently considered Significantly Overvalued. The stock's GF Value™ is ₩35,473.99, compared to a current price of ₩59,600.00 — trading 68% above its estimated fair value. The current OCF Yield % is 4.99, which is 43% below median its 10-year median of 8.77 and 179.6% above the Medical Devices & Instruments industry median of 1.79. InBody Co's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For InBody Co (XKRX:041830), the current OCF Yield % is 4.99 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InBody Co (XKRX:041830) Overvalued in 2026?
Based on GuruFocus' analysis, InBody Co stock appears to be overvalued.
The current stock price of ₩59,600.00 is trading 68% above its estimated GF Value™ of ₩35,473.99.
GuruFocus considers InBody Co to be Significantly Overvalued.
Key valuation signals for XKRX:041830:
OCF Yield %: 4.99 (43% below median its 10-year median of 8.77)
GF Value™: ₩35,473.99 vs. price of ₩59,600.00 (68% above fair value)
Industry Position: 179.6% above the Medical Devices & Instruments median (#283 of 850)
No single metric tells the full story. See the XKRX:041830 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InBody Co Ltd is a Korea-based company engaged in the manufacturing and distribution of body composition analyzers. The company mainly produces body composition analyzers under the brand name InBody and Lookin'Body. It's InBody series products include InBody720, InBody570, InBody230, InBody J30, and InBody S10.
88GF Score
Get the complete analysis for XKRX:041830
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:041830 has been successfully added to your 
